Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic gram-positive bacteria" is a collective description for a group of bacterial species that share both Gram stain positivity (due to a thick peptidoglycan cell wall) and the capacity to cause disease in humans. Key pathogenic genera include *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*, *Bacillus*, *Listeria*, and *Corynebacterium*. These organisms are major causes of diverse infectious diseases, such as pneumonia, sepsis, food poisoning, and wound infections. Treatments differ by species but often involve beta-lactams, glycopeptides, or other antibiotic classes targeting the bacterial cell wall or protein synthesis. The concept does not denote a precise molecular target but an organismal category relevant in clinical microbiology, infectious disease, and antibiotic therapy[2][3][4][5][6].
Cell wall synthesis inhibition, Protein synthesis inhibition, RNA synthesis inhibition, DNA synthesis inhibition (antibiotics act by one or more of these mechanisms; most commonly cell wall synthesis inhibition due to unique thick peptidoglycan layer)
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic gram-positive bacteria.